LeMaitre Vascular (LMAT) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
The annual meeting is scheduled for June 2, 2025, with proxy materials available online to reduce environmental impact and costs.
Shareholders will vote on director elections, executive compensation, frequency of say-on-pay votes, and auditor ratification.
The board recommends voting for all director nominees, for executive compensation, every three years for say-on-pay, and for auditor ratification.
2024 financial results showed 14% sales growth, 46% net income growth, and a 14% dividend increase.
Voting matters and shareholder proposals
Proposal 1: Elect three Class I directors for three-year terms.
Proposal 2: Advisory vote to approve 2024 executive compensation.
Proposal 3: Advisory vote on frequency of future say-on-pay votes, with board recommending every three years.
Proposal 4: Ratification of Grant Thornton LLP as independent auditor for 2025.
Shareholder proposals for the 2026 meeting must be received by December 18, 2025.
Board of directors and corporate governance
Board consists of eight members divided into three classes, with annual elections for one class.
Five directors are independent per Nasdaq standards.
Board committees: Audit, Compensation, and Nominating & Corporate Governance, all composed of independent directors.
Board leadership combines CEO and Chairman roles; no lead independent director.
Director resignation policy requires any director not receiving a majority of votes to offer resignation.
Latest events from LeMaitre Vascular
- Q3 2024 sales up 16%, EPS up 49%, with raised guidance and strong biologics-driven growth.LMAT
Q3 20248 Jul 2026 - Double-digit growth, margin gains, and higher shareholder returns drive 2025 outlook.LMAT
Q4 20248 Jul 2026 - Q2 net income up 46% on 11% sales growth; 2024 guidance raised for sales and EPS.LMAT
Q2 20248 Jul 2026 - Q1 2026 saw 11% sales and 42% EPS growth, with raised guidance and strong biologics momentum.LMAT
Q1 20268 Jul 2026 - Q4 2025 saw 16% sales and 47% profit growth; 2026 outlook features strong growth and capital returns.LMAT
Q4 202521 Apr 2026 - Votes will be held on director elections, executive pay, and auditor ratification at the June 2026 meeting.LMAT
Proxy filing14 Apr 2026 - Annual meeting to vote on directors, executive pay, and auditor, with focus on governance and performance.LMAT
Proxy filing14 Apr 2026 - Double-digit growth, global expansion, and 15 years of dividend increases drive strong outlook.LMAT
Investor presentation27 Feb 2026 - Q1 2025 saw 13% organic sales growth, margin gains, and a raised outlook amid global expansion.LMAT
Q1 202523 Dec 2025